Compare NATL & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | BEAM |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2023 | 2019 |
| Metric | NATL | BEAM |
|---|---|---|
| Price | $44.73 | $33.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $45.60 | ★ $50.75 |
| AVG Volume (30 Days) | 769.3K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 73.98 | ★ 82.31 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,354,000,000.00 | $24,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $4.24 | $33.77 |
| P/E Ratio | $155.88 | ★ N/A |
| Revenue Growth | 0.86 | ★ 33.33 |
| 52 Week Low | $23.56 | $15.60 |
| 52 Week High | $48.50 | $36.44 |
| Indicator | NATL | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 63.41 |
| Support Level | $43.47 | $25.85 |
| Resistance Level | $46.20 | $34.29 |
| Average True Range (ATR) | 0.77 | 1.84 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 45.16 | 88.07 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.